Bristol-Myers Squibb Co. missed in its effort to show PD-1 inhibitor Opdivo could improve upon standard-of-care Nexavar in first-line hepatic cell carcinoma (HCC), leaving the pharma to look for a combination regimen with CTLA-4 inhibitor Yervoy in previously treated patients, as well as monotherapy in adjuvant care.
BMS' Bid For Opdivo In First-Line HCC Stymied
Top-line results from a Phase III study testing Opdivo versus Nexavar in first-line liver cancer fail to meet OS target. Bristol points to positive numerical trend, but the results are a setback in the indication.
